Courier Capital’s Ocular Therapeutix OCUL Stock Holding History

Courier Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$572K	Buy	74,604 +2,500	+3%	+$24.5K	0.03%	274
2026 Q2	$708K	Hold	72,104	–	–	0.04%	246
2026 Q1	$611K	Buy	72,104 +2,000	+3%	+$19.1K	0.03%	250
2025 Q4	$851K	Sell	70,104 -66,162	-49%	-$804K	0.05%	225
2025 Q3	$1.59M	Sell	136,266 -18,000	-12%	-$215K	0.09%	182
2025 Q2	$1.43M	Hold	154,266	–	–	0.09%	188
2025 Q1	$1.13M	Buy	154,266 +97,828	+173%	+$752K	0.07%	197
2024 Q4	$482K	Buy	+56,438	New	+$551K	0.03%	261

Other funds holding OCUL

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Kraematon Investment Advisors Braintree, Massachusetts $134M AUM 18.69% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Courier Capital's OCUL Position: Q3 2026 in Review

Courier Capital increased its Ocular Therapeutix (OCUL) stake by 3.5% in Q3 2026, buying an estimated $24.5K and bringing the position to 74,604 shares worth $572K. The position accounts for 0.03% of the portfolio, ranked #274.

Courier Capital first reported a position in OCUL in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.59M in Q3 2025. 66 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

Courier Capital held 74,604 shares of Ocular Therapeutix worth $572K as of Q3 2026.
Courier Capital bought 2,500 Ocular Therapeutix shares in Q3 2026, an estimated $24.5K.
Ocular Therapeutix made up 0.03% of Courier Capital's portfolio in Q3 2026, its #274 holding.
Courier Capital first reported a position in Ocular Therapeutix in Q4 2024 and has held it in 8 quarters since.
Courier Capital's Ocular Therapeutix position peaked at $1.59M in Q3 2025.
66 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Courier Capital's 13F filing for Q3 2026, filed 13 Oct 2026.